Mealey's (December 2, 2020, 8:39 AM EST) -- DETROIT — The lead plaintiffs in a securities lawsuit over a pharmaceutical firm’s allegedly false statements about a cholesterol drug’s approval failed to establish the necessary conditions to justify the “highly disfavored” practice of subpoenaing the deposition of a defendant’s trial counsel, a Michigan federal magistrate judge ruled Nov. 30, granting the drug company’s motion to quash the subpoena (Kevin L. Dougherty, et al. v. Esperion Therapeutics Inc., et al., No. 16-10089, E.D. Mich., 2020 U.S. Dist. LEXIS 223221)....